PepGen is a clinical-stage biotechnology company. Co.'s primary product candidate is PGN-EDO51, an Enhanced Delivery Oligonucleotide (EDO) peptide conjugated to a phosphorodiamidate morpholino oligomers (PMO) therapeutic cargo, which it is developing for the treatment of Duchenne muscular dystrophy (DMD) patients with mutations amenable to an exon 51-skipping approach. Co. is developing PGN-EDODM1, an EDO peptide-conjugated PMO, for the treatment of myotonic dystrophy type 1. Co.'s second EDO therapeutic candidate for the treatment of DMD, and third product candidate, PGN-EDO53, is an EDO peptide-conjugated PMO designed to skip exon 53 of the dystrophin transcript. We show 6 historical shares outstanding datapoints in our coverage of PEPG's shares outstanding history.
Understanding the changing numbers of PEPG shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PEPG versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PEPG by allowing them to research PEPG shares outstanding history
as well as any other stock in our coverage universe. |
Free PEPG Email Alerts:
Video: Shares Outstanding Importance
